Ross Eberly

Cooley advised ProfoundBio, a clinical-stage biotechnology company developing novel antibody-drug conjugate therapeutics for patients with cancer, on its definitive agreement to be acquired for $1.8 billion in an all-cash transaction by Genmab (NASDAQ: GMAB), a dual-listed, international biotechnology company that creates and develops differentiated antibody therapeutics to fight against cancer and other serious diseases.

Cooley advised Community, a short message service (SMS) customer engagement platform that connects businesses, brands, political and public figures, creators, musicians, celebrities and more, on its $25 million Series B financing. Partner Dave Young led the Cooley team.

Cooley advised Jackpocket, the first licensed third-party lottery courier app in the US, on its definitive agreement to be acquired by DraftKings for $750 million.

Cooley advised Brii Biosciences on its agreements with VBI Vaccines (NASDAQ: VBIV) to ensure expansion and control of future clinical and commercial supplies of BRII-179, a late-stage clinical asset in Brii Bio’s hepatitis B virus functional cure portfolio. With operations in major biotechnology centers in the US and China, Brii Bio (HKSE: 2137) is a Hong Kong Stock Exchange-listed biotechnology company developing therapies to improve patient health and choice across diseases with high unmet needs.

Cooley advised Rubicon Technology Partners – a Boulder, Colorado-based private equity firm focused exclusively on investing in and growing software companies – on its majority strategic investment in Vimly Benefit Solutions, a leader in the benefits administration space.